A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting

Table 5

Efficacy of NEPA in older patients.

% of patients	Study 1 (HEC)		Study 2 (AC)		Study 3 (non-AC MEC/HEC)
Time period	≥65 yrs; ()	Overall population; ()	≥65 yrs; ()	Overall population; ()	≥65 yrs; ()	Overall population; ()
Acute (0–24 h)	100	98.5	94.0	88.4	97.4	92.9
Delayed (25–120 h)	100	90.4	81.0	76.9	80.8	83.2
Overall (0–120 h)	100	89.6	79.3	74.3	78.2	80.6

HEC: highly emetogenic chemotherapy; AC: anthracycline cyclophosphamide; MEC: moderately emetogenic chemotherapy.